BioScience Health Innovations (BHIC) Liabilities and Shareholders Equity (2019 - 2026)

BioScience Health Innovations (BHIC) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 67.05% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $8.2 million (up 181.62% YoY), while the FY2025 annual figure was $1.7 million, up 95.38% from the prior year.
• Liabilities and Shareholders Equity grew to $2.3 million in Q1 2026 per BHIC's latest filing, from $1.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $2.3 million in Q1 2026 and bottomed at $16253.0 in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $684338.2 across 5 years, with a median of $154798.0 in 2024.
• On a YoY basis, Liabilities and Shareholders Equity climbed as much as 6439.04% in 2022 and fell as far as 70.52% in 2022.
• BioScience Health Innovations' Liabilities and Shareholders Equity stood at $28343.0 in 2022, then soared by 229.49% to $93388.0 in 2023, then soared by 835.65% to $873788.0 in 2024, then jumped by 95.38% to $1.7 million in 2025, then surged by 36.5% to $2.3 million in 2026.
• Business Quant data shows BHIC's Liabilities and Shareholders Equity at $2.3 million in Q1 2026, $1.7 million in Q4 2025, and $2.1 million in Q3 2025.